Ticker
ACLX

Price
17.67
Stock movement down
-0.75 (-4.07%)
Company name
Arcellx Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
773.71M
Ent value
668.35M
Price/Sales
-
Price/Book
3.49
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-
3 year return
-
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ACLX does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book3.49
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count43.79M
EPS (TTM)-3.17
FCF per share (TTM)-2.00

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-62.23M
Net income (TTM)-106.45M
EPS (TTM)-3.17
EPS (1y forward)-4.15

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash127.16M
Net receivables0.00
Total current assets220.90M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets243.39M
Accounts payable1.87M
Short/Current long term debt5.21M
Total current liabilities16.81M
Total liabilities21.80M
Shareholder's equity221.59M
Net tangible assets221.59M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-61.41M
Capital expenditures (TTM)5.83M
Free cash flow (TTM)-67.24M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-48.04%
Return on Assets-43.74%
Return on Invested Capital-47.96%
Cash Return on Invested Capital-30.29%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open18.58
Daily high18.58
Daily low17.44
Daily Volume138K
All-time high24.43
1y analyst estimate29.50
Beta-
EPS (TTM)-3.17
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ACLXS&P500
Current price drop from All-time high-27.67%-12.18%
Highest price drop-62.33%-56.47%
Date of highest drop18 May 20229 Mar 2009
Avg drop from high-25.22%-11.38%
Avg time to new high18 days12 days
Max time to new high70 days1805 days
COMPANY DETAILS
ACLX (Arcellx Inc) company logo
Marketcap
773.71M
Marketcap category
Small-cap
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Employees
78
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The mean of analysts' price targets for Arcellx, Inc. (ACLX) points to a 61.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an...
September 8, 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today report...
August 15, 2022
Gaithersburg's Arcellx Inc. (NASDAQ: ACLX) has inked a deal to expand into Rockville. The newly minted public company, a clinical-stage provider of cell therapies for cancer and autoimmune diseases, ...
August 1, 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
June 23, 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
June 21, 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
June 21, 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
June 16, 2022
The American Society of Clinical Oncology (ASCO) just finished up its annual meeting. We have some winners coming out of the conference.
June 10, 2022
Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.
June 6, 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
June 3, 2022
Next page